Food and Drug Safety Center, Hadano, Kanagawa, Japan.
Mutat Res. 2012 Apr 11;744(1):30-5. doi: 10.1016/j.mrgentox.2011.12.014. Epub 2011 Dec 23.
The present protocol has been developed for the BALB/c 3T3 cell transformation assay (CTA), following the prevalidation study coordinated by the European Centre for the Validation of Alternative Methods (ECVAM) and reported in this issue (Tanaka et al. [16]). Based upon the experience gained from this effort and as suggested by the Validation Management Team (VMT), some acceptance and assessment criteria have been refined compared to those used during the prevalidation study. The present protocol thus describes cell culture maintenance, the dose-range finding (DRF) experiment and the transformation assay, including cytotoxicity and morphological transformation evaluation. Use of this protocol and of the associated photo catalogue included in this issue (Sasaki et al. [17]) is recommended for the future conduct of the BALB/c 3T3 CTA.
本方案是在欧洲替代方法验证中心(ECVAM)协调的预验证研究基础上为 BALB/c 3T3 细胞转化分析(CTA)制定的,该研究报告在本期中(Tanaka 等人,[16])。根据该工作获得的经验,并按照验证管理小组(VMT)的建议,与预验证研究相比,本方案对一些接受和评估标准进行了细化。本方案描述了细胞培养维持、剂量范围发现(DRF)实验和转化分析,包括细胞毒性和形态转化评估。推荐在未来的 BALB/c 3T3 CTA 中使用本方案和本期中包含的相关照片目录(Sasaki 等人,[17])。